Masteron Propionate — Dosing, Cycles, Half-Life & Side Effects

Masteron Propionate is a DHT-derived anabolic-androgenic steroid with a half-life of 2-3 days. Drostanolone propionate — DHT-derivative injectable used historically for breast cancer (Masteril) and in PED context for cutting/hardening via anti-estrogenic AR competition. Non-17α-alkylated; does not aromatize. Propionate ester gives 2-3 day depot half-life. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.

Quick Facts

ClassDHT
Half-life2-3 days
Detection window30 days
AromatizationNo
HepatotoxicityNone
Suppression6/10
17α-alkylatedNo
Administrationinjectable

Typical Dosing Ranges

Common dose range: 350-525mg/week

Cycle length: 8-12 weeks

Time to steady state: ~10 days

Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.

Stacking Considerations

  • No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.

PCT Requirements

  • This compound causes clinically meaningful HPTA suppression. Post-cycle therapy is recommended.
  • Depot clearance estimate: ~10 days post-last-dose before SERM start (5 × apparent depot half-life of 48h).
  • Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
  • Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.

Side Effect Profile

  • Hair loss
  • Frequent injections
  • Mild suppression
  • Acne

Known Interactions

No compound-specific interactions are catalogued in the current matrix. This does not mean no risk exists — it means there is no curated pairwise entry.

Monitoring (Bloodwork & Vitals)

  • Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
  • Lipid panel (total cholesterol, HDL, LDL, triglycerides)
  • CBC (hemoglobin, hematocrit — watch for erythrocytosis)
  • Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
  • Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)

Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.

Frequently Asked Questions

What is the half-life of Masteron Propionate?

Masteron Propionate has a half-life of approximately 2-3 days. Clearance estimate: 48h � 5 = 240h = 10 days. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.

What is the typical dose range for Masteron Propionate?

Commonly reported ranges for Masteron Propionate: 350-525mg/week. Cycle length: 8-12 weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.

Does Masteron Propionate suppress natural testosterone?

Masteron Propionate causes strong suppression of the HPTA axis (score 6/10). Post-cycle therapy (PCT) is recommended after use.

Does Masteron Propionate aromatize to estrogen?

Aromatization profile: No. Minimal to no aromatization expected, so aromatase inhibitors are not typically indicated for this compound alone.

What is Masteron Propionate typically used for?

Masteron Propionate is commonly used for: Cutting, Contest prep, Intermediate users. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.

Citations

  1. FDA prescribing information (NDA historical). 2004. FDA NDA (drostanolone propionate) — Half-life 2-2.5 days for propionate ester; FDA-approved for breast cancer
  2. Liu et al.. 2025. Substance Use & Misuse — AAS meta-analysis: SBP +12.43 mmHg (95% CI: 9.59-15.26), LDL-C +9.12 mg/dL (95% CI: 6.75-11.49)
  3. Hartgens F, Kuipers H. 2004. Sports Med — Propionate-ester AAS depot kinetics ~2 days; supports EOD-E3.5D injection schedules. esterHalfLifeDays 0.8 reflects ester hydrolysis t½, distinct from depot t½.
  4. Bennett MB, Helman P, Palmer P. 1975. S Afr Med J — Masteril (drostanolone propionate) clinical RCT in pre/peri/postmenopausal breast cancer 1968-1972; 44% response premenopausal, 38.5% postmenopausal — original FDA-approved indication
  5. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004

Disclaimer

StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use Masteron Propionate. Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.

Skip to main content